Prevalence of Sarcopenia and Sarcopenic Obesity in Older Adults

February 26, 2020 updated by: Filiz Demirdağ, Goztepe Training and Research Hospital

Prevalence of Sarcopenia and Sarcopenic Obesity in Community-dwelling Outpatient Older Adults

Syndromes such as sarcopenia, sarcopenic obesity and osteosarcopenic obesity are commonly seen in older adults. They result from the impairment of muscle, bone and adipose tissue. Thus, they lead to a decrease in quality of life and increase morbidity and mortality. The aim of this study is to report the prevalence of sarcopenia, sarcopenic obesity and osteosarcopenic obesity in community-dwelling outpatient older adults and to investigate the related factors.

Study Overview

Study Type

Observational

Enrollment (Actual)

572

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Istanbul, Turkey, 34722
        • Goztepe Training and Research Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

65 years and older (OLDER_ADULT)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

Community-dwelling older adults

Description

Inclusion Criteria:

  • Being at the age of 65 or older
  • Being able to complete 4-m walk test

Exclusion Criteria:

  • <24 points on Mini-Mental State Examination
  • 12 points or higher on Geriatric Depression Scale

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Handgrip Strength
Time Frame: 10 minutes
Handgrip strength measured by Takei© Hand Dynamometer
10 minutes
Muscle mass
Time Frame: 5 minutes
Using Bioimpedance analysis (BİA) technique with TANITA© TBF 300
5 minutes
Bone density
Time Frame: 30 minutes
T score evaluation using Dual-energy X-ray absorptiometry (DEXA)
30 minutes
Percentage of body fat
Time Frame: 5 minutes
Using Bioimpedance analysis (BİA) technique with TANITA© TBF 300
5 minutes

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Gait speed
Time Frame: 3 minutes
4-m usual walking speed test
3 minutes
Physical Activity
Time Frame: 5-10 minutes
Using Rapid Assessment of Physical Activity (RAPA)
5-10 minutes
Nutritional Status
Time Frame: 10 minutes
Assessed with Mini-Nutritional Assessment (MNA)
10 minutes
Activities of Daily Living
Time Frame: 10 minutes
Activities of daily living assessed with Katz Index of Independence in Activities of Daily Living
10 minutes
Instrumental Activities of Daily Living
Time Frame: 10 minutes
Instrumental activities of daily living assessed with Lawton -Brody Instrumental Activities of Daily Living Scale
10 minutes
Depression
Time Frame: 10 minutes
Assessed with The Geriatric Depression Scale- Short Form
10 minutes
Mini-Mental State Examination
Time Frame: 10-15 minutes
Mini-Mental State Examination
10-15 minutes
Blood Sample Analysis
Time Frame: 5 minutes
A blood sample analysis including parameters such as: wbc, hgb, htc, mcv ,plt, fasting blood sugar, urea, uric acid, creatin, AST, ALP, ALT, GGT, LDH, total colesterol, trigylicerid, LDL, HDL, NA, K, Mg, Ca, P, Albumin, protrombin time, CRP, B12, folate, iron, ferritin, PTH, vitamin-D, sedimentation, TSH, T4, insukin, HGBA1C, IHOMA-IR.
5 minutes
Comorbidities
Time Frame: 5 minutes
Assessed with Charlson Comorbidity Index
5 minutes

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

October 7, 2019

Primary Completion (ACTUAL)

January 1, 2020

Study Completion (ACTUAL)

January 1, 2020

Study Registration Dates

First Submitted

October 7, 2019

First Submitted That Met QC Criteria

October 9, 2019

First Posted (ACTUAL)

October 10, 2019

Study Record Updates

Last Update Posted (ACTUAL)

February 28, 2020

Last Update Submitted That Met QC Criteria

February 26, 2020

Last Verified

February 1, 2020

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Sarcopenia

3
Subscribe